Caribou Biosciences Inc
Stock Watch
Stock Watch will tell you what changes at Caribou Biosciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 1.20 $ to 2.80 $ · Last price: 1.20 $ (As of: October 2, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 10/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Caribou Biosciences Inc CRBU | 0.1 | – | -36.9 | -735.6 | -1,096.4 | 11.7 | -45.3 |
| Vertex Pharmaceuticals Inc VRTX | 127.6 | 30.6 | 24.4 | 55.0 | 38.1 | 9.6 | 23.5 |
| Regeneron Pharmaceuticals Inc REGN | 76.4 | 18.5 | 13.5 | 44.5 | 20.7 | 1.0 | 23.2 |
| Moderna Inc MRNA | 75.4 | – | 4.6 | -66.0 | -131.1 | -39.2 | 584.6 |
| argenx NV ARGX | 57.2 | 35.1 | 30.7 | 59.1 | 32.0 | 89.6 | 16.1 |
| Revolution Medicines Inc RVMD | 43.0 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 352.2 |
| BeiGene, Ltd. ONC | 40.5 | 63.9 | 33.7 | 88.9 | 19.1 | 40.2 | 7.4 |
| Royalty Pharma Plc RPRX | 31.5 | 30.9 | 19.2 | 95.8 | 100.3 | 5.1 | 61.8 |
| Alnylam Pharmaceuticals Inc ALNY | 29.2 | 55.3 | 28.6 | 79.7 | 23.0 | 65.2 | -52.3 |
| Median of companies shown | 43.0 | 33.0 | 19.2 | 55.0 | 20.7 | 9.6 | 23.2 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 6 | -34 | -23 | -0.85 | -32 | 7 | 62 |
| 2020 | 12 | -36 | -34 | -1.24 | -33 | -23 | 36 |
| 2021 | 10 | -67 | -67 | -1.11 | -33 | 388 | 442 |
| 2022 | 14 | -106 | -99 | -1.64 | -91 | 301 | 374 |
| 2023 | 34 | -116 | -102 | -1.38 | -93 | 368 | 432 |
| 2024 | 10 | -167 | -149 | -1.65 | -138 | 253 | 313 |
| 2025 | 11 | -136 | -148 | -1.59 | -111 | 122 | 175 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q2 | -0.44 | 10.20 | 4 | -7.70 | -1,088.30 | -33 | -35 |
| 2024: Q3 | -0.38 | -216.70 | 2 | -91.40 | -1,713.60 | -33 | -33 |
| 2024: Q4 | -0.39 | 0.00 | 2 | -41.60 | -1,708.70 | -36 | -36 |
| 2025: Q1 | -0.44 | 6.40 | 2 | -3.10 | -1,699.60 | -37 | -38 |
| 2025: Q2 | -0.58 | -31.80 | 3 | -23.00 | -2,028.40 | -28 | -29 |
| 2025: Q3 | -0.30 | 21.10 | 2 | 8.60 | -1,253.30 | -25 | -25 |
| 2025: Q4 | -0.28 | 28.20 | 4 | 89.70 | -672.10 | -21 | -21 |
| 2026: Q1 | -0.26 | 40.90 | 2 | 1.90 | -1,046.50 | -27 | -27 |
| 2026: Q2 | -0.24 | 58.60 | 2 | -44.40 | -1,620.00 | -23 | -23 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Backtested Scanners
Growth
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.18 | -1.31 – -1.06 | 25 | – | 4 |
| 12/31/2027 | -1.26 | -1.42 – -1.14 | 30 | -7.5% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -7.0%
- More than 10% revenue growth is expected for the coming year -80.5%
- Share count grows by less than 3% a year 15.4%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -995.2%
- Gross margin at 40% or higher and without meaningful erosion 67.3%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 112 m net cash
- Operating cash flow covers the profits of the last three years 57 m
- Return on capital at 15% or higher, or up versus two years ago -90.8%
- Insiders hold at least 10% or are net buyers 8.9%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 11.6%
- Exp. sales growth 3Y > 5% 63.4%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 63.4%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -121.2%
- ROCE > 15% -90.8%
- Expected return > 10% -92.2%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Caribou Biosciences, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit Genom-Editierung mittels CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) befasst. Es bietet eine Genom-Editierungsplattform auf Basis neuartiger CRISPR-Hybrid-RNA-DNA-Genom-Editierungstechnologie, die präzise Genom-Editierung allogener Zelltherapien ermöglicht. Das Unternehmen entwickelt Vispacabtagene Regedleucel, eine allogene Anti-CD19-CAR-T-Zelltherapie, die sich in einer Phase-1-Studie zur Behandlung von rezidiviertem oder refraktärem B-Zell-Non-Hodgkin-Lymphom befindet; sowie CB-011, eine allogene Anti-BCMA-CAR-T-Zelltherapie, die sich in einer Phase-1-Studie zur Behandlung von rezidiviertem oder refraktärem multiplem Myelom befindet. Caribou Biosciences, Inc. wurde 2011 gegründet und hat ihren Hauptsitz in Berkeley, Kalifornien.
- Employees
- 97
- Headquarters
- Berkeley, CA
- Address
- 2929 7th Street, 94710 Berkeley, United States
- Phone
- 510 982 6030
- Website
- cariboubio.com
- IPO Date
- 07/23/2021
- ISIN
- US1420381089
Management
| Name | Title | Birth Year |
|---|---|---|
| Rachel E. Haurwitz Ph.D. | Co-Founder, CEO, President & Director | 1986 |
| Sriram Ryali M.B.A. | Chief Financial Officer | 1982 |
| Barbara G. McClung Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1955 |
| Jennifer A. Doudna Ph.D. | Co-founder & Member of Scientific Advisory Board | 1964 |
| Ryan Fischesser | Interim Principal Accounting Officer & Controller | – |
| Reigin Zawadzki | Chief People Officer | – |
| Tina Albertson M.D., Ph.D. | Chief Medical Officer | 1974 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/13/2026 Caribou Biosciences, Inc. (CRBU): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.